Published Randomized Comparative Data Demonstrate Superior Outcomes with Dayspring in Adults Aged 65 and Older and Patients with Phlebolymphedema

Two TEAYS subgroup analyses reported significantly better outcomes for Koya Medical’s Dayspring vs an advanced pneumatic compression device in lower-extremity lymphedema. In adults ≥65, Dayspring reduced limb volume by 353.9 mL vs -10.7 mL (p<0.05), improved LYMQOL by +1.43 vs -0.10 (p<0.05), and increased adherence to 86% vs 55% (p<0.001), with 77% preferring Dayspring (vs 23%). In phlebolymphedema, Dayspring reduced limb volume by 424.4 mL vs 50.8 mL (p=0.0085), improved LYMQOL by +1.39 vs +0.18 (p=0.01), and raised adherence to 81% vs 49% (p≤0.001), with 85% preference (vs 15%).

Analysis

The main economic winner is not just Koya; it is the non-pneumatic compression category if payers believe adherence is the real driver of outcomes. Better compliance in older, mobility-limited patients is a reimbursement argument, not merely a clinical one, and that can shift buying behavior from device-form-factor comparisons to total cost of care: fewer abandoned treatments, fewer repeat orders, and potentially better downstream utilization in wound/venous clinics. The obvious loser is the incumbent APCD ecosystem, with Tactile Medical (TCMD) the cleanest public read-through if referral networks start to view mobile compression as the higher-conviction default.

Near term, this is mostly a marketing and payer-engagement catalyst, not a revenue step-function. The trial is still small and crossover-based, so the key question is whether the data are compelling enough for Medicare Advantage, commercial payers, and durable medical equipment channels to loosen prior authorization or broaden coverage; without that, physician enthusiasm can outrun actual units. Over 1-3 months, watch for payer policy language, distributor commentary, and any change in conversion rates; over 6-18 months, the real test is whether this becomes a reimbursed category shift or just another differentiated SKU with modest share gain.

Consensus may be underestimating how strongly adherence can re-rate a device category when the buyer is a payer, not a clinician. The contrarian risk is that the market extrapolates too much from subgroup analyses while ignoring the operational friction of fitting, training, and scaling a prescription device in elderly patients. If TCMD commentary does not show any pressure on win rates or if Koya fails to translate evidence into coverage wins, the thesis is falsified quickly; if reimbursement improves, the move could be structural rather than event-driven.

Key Decisions for Investors

• Watchlist: short TCMD on any rally tied to compression-therapy enthusiasm; best entry is after channel checks confirm Dayspring is showing up in payer discussions, with a 1-3 month horizon and downside driven by share-loss risk rather than immediate earnings reset.
• Pair trade idea: long any diversified medtech exposure to outpatient, reimbursement-backed devices vs. short TCMD if evidence-based compression adoption accelerates; thesis works only if payers reward adherence data with coverage wins.
• No urgent trade in Koya absent a ticker, but flag it for financing/partnering optionality: if commercial traction emerges, this evidence package could support strategic interest from larger DME or medtech buyers within 6-18 months.
• Set an alert for payer policy changes or CMS/local coverage decisions on lymphedema compression; absence of coverage expansion by the next reimbursement cycle would materially weaken the competitive-read-through thesis.